Treating Lupus with CAR-T Cell Therapy - Yale Medicine Explains

Why It Matters

CAR‑T offers a potentially curative, one‑time solution for refractory lupus, signaling a paradigm shift in autoimmune therapy and opening pathways for similar treatments across multiple diseases.

Key Takeaways

• CAR‑T therapy repurposes engineered T cells to target lupus‑driven B cells.
• Early Yale trials show depletion of autoreactive B cells and disease remission.
• Naïve B‑cell reconstitution after CAR‑T lacks autoimmune hallmarks.
• Single infusion often suffices, offering potential durable remission for refractory lupus.
• Success could expand CAR‑T use to other autoimmune disorders like scleroderma.

Summary

The video explains how Yale Medicine is adapting CAR‑T cell therapy—originally approved for blood cancers—to treat systemic lupus erythematosus. By extracting a patient’s T cells, re‑programming them to recognize and destroy pathogenic B cells, and reinfusing them, researchers aim to reset the autoimmune cascade that drives organ damage.

Key insights include the therapy’s mechanism: CAR‑T cells indiscriminately eliminate both malignant and autoreactive B cells, after which the bone marrow repopulates with naïve B cells that lack the disease‑causing antibodies. Early trial data show rapid depletion of autoreactive B cells, clinical remission in several participants, and durable effects after a single infusion, contrasting with the chronic dosing required for existing lupus drugs.

Dr. Miller emphasizes, “We don’t usually give CAR‑T cells more than once,” and notes that “there’s good biological reason to think the CAR‑T cells could be curing some of these patients.” The discussion also highlights that the same platform is being explored for scleroderma and multiple sclerosis, underscoring its broader autoimmune potential.

If these findings hold, CAR‑T could become a one‑time, disease‑modifying therapy for patients who have exhausted standard treatments, reshaping the therapeutic landscape for lupus and potentially other autoimmune diseases while reducing long‑term drug burden and healthcare costs.

Original Description

For more information on CAR-T cell therapies or #YaleMedicine, visit: https://www.yalemedicine.org/conditions/car-t-cell-therapy.

Drug therapies that harness the immune system’s natural ability to fight cancer have been advancing at a fast pace since the first immunotherapy drug was approved in 2011. These early immunotherapy drugs—called checkpoint inhibitors—work by triggering the immune system to attack cancer cells. But a new and highly personalized type of immunotherapy drug uses a patient’s synthetically modified T cells—a type of white blood cell—to kill cancer cells. This is called chimeric antigen receptor (CAR) T-cell therapy. Think of your T-cells as police officers on a beat. They patrol the body’s bloodstream in search of foreign invaders, from harmful bacteria to cancer cells. They have specialized receptors that recognize these unwanted intruders by detecting certain proteins on their surfaces. In CAR T-cell therapy, synthetically engineered receptors designed to detect the cancer cell’s protein are attached to a sample of a patient’s T-cells taken from a blood draw. Then, in a laboratory, hundreds of millions of these modified T-cells are grown before the cells are re-infused back into the patient. If the therapy is successful, these cells begin recognizing and killing cancer cells. "CAR T is an exciting new form of immunotherapy that is proving effective in patients with certain recurrent or resistant blood cancers,” says Yale Medicine hematologist Stuart Seropian, MD, who is co-director of the CAR T-Cell Therapy program at Yale New Haven Health’s Smilow Cancer Hospital, the first hospital in Connecticut to perform the therapy. At Yale Medicine, CAR T-cell therapy offers highly personalized therapy options for patients with certain types of blood cancers such as relapsed or refractory B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma.

0:00 CAR T-Cell Therapy

1:37 Lupus